Prognostic factors and treatment of patients with chondrosarcoma: a single institutional experience

Tuğba Önder; Ülkü Yalçıntaş; Öztürk Ateş; Necati Alkış

Makale detayları

Prognostic factors and treatment of patients with chondrosarcoma: a single institutional experience

Yazarlar:

Tuğba Önder | Ülkü Yalçıntaş | Öztürk Ateş | Necati Alkış

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 5, pp.657-664

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358271

pISSN:

2718-0115

Anahtar kelimeler:

Özet:

 Aims: Prognostic factors and treatment modalities in chondrosarcoma CS remain poorly defined. This study aimed to present our institutional experience with CS patients. Methods: We retrospectively reviewed the medical records of 69 CS patients treated at our Cancer Institute between 2010 and 2023. Results: Median age at diagnosis was 47 years, with a slight male predominance 52 and a median follow-up of 93 months. Grade 1 34 and grade 2 34 tumors were most common, predominantly affecting the lower extremities 40 and pelvis 26. At presentation, 63 patients had localized disease and 6 had metastases; metastases later developed in 13 additional patients, most frequently in the lungs. All 63 patients with localized disease underwent surgery, and 7 received adjuvant chemotherapy CT. Recurrence developed in 26 patients, of whom 9 were treated with systemic therapy. Among 6 patients with stage IV disease, 5 underwent palliative surgery and received CT. The most commonly used regimens included doxorubicin based CT, pazopanib, sirolimus, and celecoxib. Among patients who developed metastasis during follow-up, 1213 died. The median time from diagnosis to metastasis was 17.0 months 95 CI: 10.823.1, and median survival thereafter was 21.0 months 95 CI: 12.729.2. All six patients metastatic at presentation died, with a median progression-free survival of 7.0 months 95 CI: 2.111.8 and OS of 12.0 months 95 CI: 0.033.6. OS was 75, 63, and 57 at 5, 10, and 15 years, respectively. Female sex, lowintermediate grade, and stage III disease correlated with better OS in univariate analysis, but only stage at diagnosis remained significant in multivariate analysis p0.002. Conclusion: Our findings highlight that early tumor stage is the only independent predictor of overall survival, underscoring the critical importance of early diagnosis and timely intervention in CS.

 Aims: Prognostic factors and treatment modalities in chondrosarcoma CS remain poorly defined. This study aimed to present our institutional experience with CS patients. Methods: We retrospectively reviewed the medical records of 69 CS patients treated at our Cancer Institute between 2010 and 2023. Results: Median age at diagnosis was 47 years, with a slight male predominance 52 and a median follow-up of 93 months. Grade 1 34 and grade 2 34 tumors were most common, predominantly affecting the lower extremities 40 and pelvis 26. At presentation, 63 patients had localized disease and 6 had metastases; metastases later developed in 13 additional patients, most frequently in the lungs. All 63 patients with localized disease underwent surgery, and 7 received adjuvant chemotherapy CT. Recurrence developed in 26 patients, of whom 9 were treated with systemic therapy. Among 6 patients with stage IV disease, 5 underwent palliative surgery and received CT. The most commonly used regimens included doxorubicin based CT, pazopanib, sirolimus, and celecoxib. Among patients who developed metastasis during follow-up, 1213 died. The median time from diagnosis to metastasis was 17.0 months 95 CI: 10.823.1, and median survival thereafter was 21.0 months 95 CI: 12.729.2. All six patients metastatic at presentation died, with a median progression-free survival of 7.0 months 95 CI: 2.111.8 and OS of 12.0 months 95 CI: 0.033.6. OS was 75, 63, and 57 at 5, 10, and 15 years, respectively. Female sex, lowintermediate grade, and stage III disease correlated with better OS in univariate analysis, but only stage at diagnosis remained significant in multivariate analysis p0.002. Conclusion: Our findings highlight that early tumor stage is the only independent predictor of overall survival, underscoring the critical importance of early diagnosis and timely intervention in CS.

 Aims: Prognostic factors and treatment modalities in chondrosarcoma CS remain poorly defined. This study aimed to present our institutional experience with CS patients. Methods: We retrospectively reviewed the medical records of 69 CS patients treated at our Cancer Institute between 2010 and 2023. Results: Median age at diagnosis was 47 years, with a slight male predominance 52 and a median follow-up of 93 months. Grade 1 34 and grade 2 34 tumors were most common, predominantly affecting the lower extremities 40 and pelvis 26. At presentation, 63 patients had localized disease and 6 had metastases; metastases later developed in 13 additional patients, most frequently in the lungs. All 63 patients with localized disease underwent surgery, and 7 received adjuvant chemotherapy CT. Recurrence developed in 26 patients, of whom 9 were treated with systemic therapy. Among 6 patients with stage IV disease, 5 underwent palliative surgery and received CT. The most commonly used regimens included doxorubicin based CT, pazopanib, sirolimus, and celecoxib. Among patients who developed metastasis during follow-up, 1213 died. The median time from diagnosis to metastasis was 17.0 months 95 CI: 10.823.1, and median survival thereafter was 21.0 months 95 CI: 12.729.2. All six patients metastatic at presentation died, with a median progression-free survival of 7.0 months 95 CI: 2.111.8 and OS of 12.0 months 95 CI: 0.033.6. OS was 75, 63, and 57 at 5, 10, and 15 years, respectively. Female sex, lowintermediate grade, and stage III disease correlated with better OS in univariate analysis, but only stage at diagnosis remained significant in multivariate analysis p0.002. Conclusion: Our findings highlight that early tumor stage is the only independent predictor of overall survival, underscoring the critical importance of early diagnosis and timely intervention in CS.

 Amaç ve Hedefler: Kondrosarkom KS hastalarının prognostik faktörleri ve tedavi yöntemlerine ilişkin veriler sınırlıdır. KS hastalarımızla ilgili deneyimlerimizi sunmayı amaçladık. Gereç ve Yöntemler: 2010-2023 yılları arasında Kanser Enstitümüzde KS tanısı almış 69 hastanın tıbbi kayıtları retrospektif olarak incelendi. Bulgular: Ortanca yaş 47 idi; 93 aylık takipte hafif bir erkek predominansı 52 gözlendi. Grade 1 34 ve 2 34 KSler en sık görülenlerdi ve alt ekstremiteler 40 ve pelvis 26 için bir eğilim vardı. 63 hasta lokalize hastalık, 6 hasta ise metastazla presente oldu. Takip sırasında 13 hastada daha metastaz görüldü. Akciğer en sık metastaz bölgesiydi. Lokalize hastalığı olan 63 hastanın tamamı ameliyat edildi; 7 hasta adjuvan kemoterapi CT aldı. 26 hastada nüks görüldü; 9 hasta sistemik kanser tedavisi aldı. Evre 4 hastalık tanısı alan 6 hastanın 5 ine palyatif cerrahi uygulandı, 5 ine CT uygulandı. En sık kullanılan tedavi rejimleri doksorubisin bazlı CT, pazopanib, sirolimus ve selekoksib idi. Takip sırasında metastaz gelişen 13 hastanın 12si hayatını kaybetti; tanıdan metastaza kadar geçen medyan süre 17,0 95 CI: 10,8-23,1 ve metastaz sonrası medyan sağ kalım 21,0 95 CI: 12,7-29,2 aydı. Başlangıçta metastatik olan altı hastanın tamamı hayatını kaybetmişti; medyan progresyonsuz sağ kalım 7 95 CI: 2,1-11,8 ve genel sağ kalım OS 12 95 CI: 0,00-33,60 aydı. OS, tüm grup için sırasıyla 5, 10 ve 15. yıllarda 75, 63 ve 57 idi. Tek değişkenli analizde kadın cinsiyet, düşük-orta grade, evre 1-2 tümörler uzamış OS ile ilişkiliydi. Çok değişkenli analizde, tanı anındaki evre OS için tek anlamlı faktördü p0,002. Sonuç: Yapılan analizler, tümörün erken evrede olmasının iyileşmiş genel sağkalım için önemli bir faktör olduğunu ortaya koydu.

Makale detayları

Prognostic factors and treatment of patients with chondrosarcoma: a single institutional experience

Yazarlar:

Tuğba Önder | Ülkü Yalçıntaş | Öztürk Ateş | Necati Alkış

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 5, pp.657-664

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358271

pISSN:

2718-0115

Chemotherapy

surgery

radiotherapy

lung metastasis

chondrosarcomaKemoterapi

cerrahi

radyoterapi

akciğer metastazı

kondrosarkom

Sayı

Makale detayları

Yazarlar: Tuğba Önder | Ülkü Yalçıntaş | Öztürk Ateş | Necati Alkış

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Klinik Onkoloji

Dergi: Anatolian Current Medical Journal Vol.7 Issue 5, pp.657-664

Belge Tipi: Makale

Yayın Tarihi: 9/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001358271

pISSN: 2718-0115

Sayı

Yazarlar:

Tuğba Önder | Ülkü Yalçıntaş | Öztürk Ateş | Necati Alkış

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 5, pp.657-664

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358271

pISSN:

2718-0115